Long term prognosis of fatty liver: risk of chronic liver disease and death
Background and aims: Fatty liver is a common histological finding in human liver biopsy specimens. It affects 10–24% of the general population and is believed to be a marker of risk of later chronic liver disease. The present study examined the risk of development of cirrhotic liver disease and the...
Gespeichert in:
| Veröffentlicht in: | Gut 2004-05, Vol.53 (5), p.750-755 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 755 |
|---|---|
| container_issue | 5 |
| container_start_page | 750 |
| container_title | Gut |
| container_volume | 53 |
| creator | Dam-Larsen, S Franzmann, M Andersen, I B Christoffersen, P Jensen, L B Sørensen, T I A Becker, U Bendtsen, F |
| description | Background and aims: Fatty liver is a common histological finding in human liver biopsy specimens. It affects 10–24% of the general population and is believed to be a marker of risk of later chronic liver disease. The present study examined the risk of development of cirrhotic liver disease and the risk of death in a cohort diagnosed with pure fatty liver without inflammation. Methods: A total of 215 patients who had a liver biopsy performed during the period 1976–1987 were included in the study. The population consisted of 109 non-alcoholic and 106 alcoholic fatty liver patients. Median follow up time was 16.7 (0.2–21.9) years in the non-alcoholic and 9.2 (0.6–23.1) years in the alcoholic group. Systematic data collection was carried out by review of all medical records. All members of the study cohort were linked through their unique personal identification number to the National Registry of Patients and the nationwide Registry of Causes of Death, and all admissions, discharge diagnoses, and causes of death were obtained. Results: In the non-alcoholic fatty liver group, one patient developed cirrhosis during the follow up period compared with 22 patients in the alcoholic group. Survival estimates were significantly (p |
| doi_str_mv | 10.1136/gut.2003.019984 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1774026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4014108291</sourcerecordid><originalsourceid>FETCH-LOGICAL-b586t-b44e54d14edf25d12cf35e957faa80c2691825cec12697e11f61f9bdc21752b43</originalsourceid><addsrcrecordid>eNqFkEtvEzEURi0EoqGwZodGQmwqTerrx9hmgYSiQlEiYAHdWh6PnThNxqk9qei_x9FEfay6snXv8edPB6H3gKcAtDlf7ocpwZhOMSgl2Qs0AdbImhIpX6IJxiBqLpg6QW9yXmOMpVTwGp0Ax5Jw1UzQfBH7ZTW4tK12KS77mEOuoq-8GYa7ahNuXfpcpZCvD0O7SrEPdhxXXcjOZFeZvqs6Z4bVW_TKm012747nKfr77eLP7LJe_Pr-Y_Z1UbdcNkPdMuY464C5zhPeAbGecqe48MZIbEmjoJSzzkK5CgfgG_Cq7SwBwUnL6Cn6Mubu9u3Wddb1QzIbvUtha9Kdjibop5s-rPQy3moQgmHSlICPx4AUb_YuD3od96kvnQ-IooRJhQt1PlI2xZyT8_c_ANYH-7rY1wf7erRfXnx4XOyBP-ouwKcjYLI1G59Mb0N-xAkASUXh6pELeXD_7vcmXetGUMH1z6uZ_k3nc6BXXM8Lfzby7Xb9bMv_H3Cp6A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779324890</pqid></control><display><type>article</type><title>Long term prognosis of fatty liver: risk of chronic liver disease and death</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Dam-Larsen, S ; Franzmann, M ; Andersen, I B ; Christoffersen, P ; Jensen, L B ; Sørensen, T I A ; Becker, U ; Bendtsen, F</creator><creatorcontrib>Dam-Larsen, S ; Franzmann, M ; Andersen, I B ; Christoffersen, P ; Jensen, L B ; Sørensen, T I A ; Becker, U ; Bendtsen, F</creatorcontrib><description>Background and aims: Fatty liver is a common histological finding in human liver biopsy specimens. It affects 10–24% of the general population and is believed to be a marker of risk of later chronic liver disease. The present study examined the risk of development of cirrhotic liver disease and the risk of death in a cohort diagnosed with pure fatty liver without inflammation. Methods: A total of 215 patients who had a liver biopsy performed during the period 1976–1987 were included in the study. The population consisted of 109 non-alcoholic and 106 alcoholic fatty liver patients. Median follow up time was 16.7 (0.2–21.9) years in the non-alcoholic and 9.2 (0.6–23.1) years in the alcoholic group. Systematic data collection was carried out by review of all medical records. All members of the study cohort were linked through their unique personal identification number to the National Registry of Patients and the nationwide Registry of Causes of Death, and all admissions, discharge diagnoses, and causes of death were obtained. Results: In the non-alcoholic fatty liver group, one patient developed cirrhosis during the follow up period compared with 22 patients in the alcoholic group. Survival estimates were significantly (p<0.01) different between the two groups, for men as well as for women, with a higher death rate in the alcoholic fatty liver group. Survival estimates in the non-alcoholic fatty liver group were not different from the Danish population. Conclusions: This study revealed that patients with type 1 non-alcoholic fatty liver disease have a benign clinical course without excess mortality.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>EISSN: 1458-3288</identifier><identifier>DOI: 10.1136/gut.2003.019984</identifier><identifier>PMID: 15082596</identifier><identifier>CODEN: GUTTAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Society of Gastroenterology</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Alcohol use ; ASAT ; aspartate aminotransferase ; Biological and medical sciences ; Biomarkers - blood ; BMI ; body mass index ; Chronic Disease ; cirrhosis ; Data collection ; Diabetes ; epidemiology ; fatty liver ; Fatty Liver - complications ; Fatty Liver, Alcoholic - complications ; Female ; Follow-Up Studies ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis ; Hospitals ; Humans ; ICD ; Insulin resistance ; International Classification of Diseases ; Liver ; liver biopsy ; Liver cirrhosis ; Liver Cirrhosis - etiology ; Liver Cirrhosis - pathology ; Liver diseases ; LPR ; Male ; Medical prognosis ; Medical records ; Medical sciences ; Middle Aged ; Mortality ; NAFLD ; NASH ; non-alcoholic fatty liver disease ; non-alcoholic steatohepatitis ; Obesity ; Pathology ; Patients ; Personal identification numbers ; Prognosis ; Risk Assessment ; Studies ; Survival Analysis ; the national registry of patients</subject><ispartof>Gut, 2004-05, Vol.53 (5), p.750-755</ispartof><rights>Copyright 2004 by Gut</rights><rights>2004 INIST-CNRS</rights><rights>Copyright: 2004 Copyright 2004 by Gut</rights><rights>Copyright © Copyright 2004 by Gut 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b586t-b44e54d14edf25d12cf35e957faa80c2691825cec12697e11f61f9bdc21752b43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774026/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774026/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15711837$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15082596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dam-Larsen, S</creatorcontrib><creatorcontrib>Franzmann, M</creatorcontrib><creatorcontrib>Andersen, I B</creatorcontrib><creatorcontrib>Christoffersen, P</creatorcontrib><creatorcontrib>Jensen, L B</creatorcontrib><creatorcontrib>Sørensen, T I A</creatorcontrib><creatorcontrib>Becker, U</creatorcontrib><creatorcontrib>Bendtsen, F</creatorcontrib><title>Long term prognosis of fatty liver: risk of chronic liver disease and death</title><title>Gut</title><addtitle>Gut</addtitle><description>Background and aims: Fatty liver is a common histological finding in human liver biopsy specimens. It affects 10–24% of the general population and is believed to be a marker of risk of later chronic liver disease. The present study examined the risk of development of cirrhotic liver disease and the risk of death in a cohort diagnosed with pure fatty liver without inflammation. Methods: A total of 215 patients who had a liver biopsy performed during the period 1976–1987 were included in the study. The population consisted of 109 non-alcoholic and 106 alcoholic fatty liver patients. Median follow up time was 16.7 (0.2–21.9) years in the non-alcoholic and 9.2 (0.6–23.1) years in the alcoholic group. Systematic data collection was carried out by review of all medical records. All members of the study cohort were linked through their unique personal identification number to the National Registry of Patients and the nationwide Registry of Causes of Death, and all admissions, discharge diagnoses, and causes of death were obtained. Results: In the non-alcoholic fatty liver group, one patient developed cirrhosis during the follow up period compared with 22 patients in the alcoholic group. Survival estimates were significantly (p<0.01) different between the two groups, for men as well as for women, with a higher death rate in the alcoholic fatty liver group. Survival estimates in the non-alcoholic fatty liver group were not different from the Danish population. Conclusions: This study revealed that patients with type 1 non-alcoholic fatty liver disease have a benign clinical course without excess mortality.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alcohol use</subject><subject>ASAT</subject><subject>aspartate aminotransferase</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>BMI</subject><subject>body mass index</subject><subject>Chronic Disease</subject><subject>cirrhosis</subject><subject>Data collection</subject><subject>Diabetes</subject><subject>epidemiology</subject><subject>fatty liver</subject><subject>Fatty Liver - complications</subject><subject>Fatty Liver, Alcoholic - complications</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis</subject><subject>Hospitals</subject><subject>Humans</subject><subject>ICD</subject><subject>Insulin resistance</subject><subject>International Classification of Diseases</subject><subject>Liver</subject><subject>liver biopsy</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver diseases</subject><subject>LPR</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>NAFLD</subject><subject>NASH</subject><subject>non-alcoholic fatty liver disease</subject><subject>non-alcoholic steatohepatitis</subject><subject>Obesity</subject><subject>Pathology</subject><subject>Patients</subject><subject>Personal identification numbers</subject><subject>Prognosis</subject><subject>Risk Assessment</subject><subject>Studies</subject><subject>Survival Analysis</subject><subject>the national registry of patients</subject><issn>0017-5749</issn><issn>1468-3288</issn><issn>1458-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkEtvEzEURi0EoqGwZodGQmwqTerrx9hmgYSiQlEiYAHdWh6PnThNxqk9qei_x9FEfay6snXv8edPB6H3gKcAtDlf7ocpwZhOMSgl2Qs0AdbImhIpX6IJxiBqLpg6QW9yXmOMpVTwGp0Ax5Jw1UzQfBH7ZTW4tK12KS77mEOuoq-8GYa7ahNuXfpcpZCvD0O7SrEPdhxXXcjOZFeZvqs6Z4bVW_TKm012747nKfr77eLP7LJe_Pr-Y_Z1UbdcNkPdMuY464C5zhPeAbGecqe48MZIbEmjoJSzzkK5CgfgG_Cq7SwBwUnL6Cn6Mubu9u3Wddb1QzIbvUtha9Kdjibop5s-rPQy3moQgmHSlICPx4AUb_YuD3od96kvnQ-IooRJhQt1PlI2xZyT8_c_ANYH-7rY1wf7erRfXnx4XOyBP-ouwKcjYLI1G59Mb0N-xAkASUXh6pELeXD_7vcmXetGUMH1z6uZ_k3nc6BXXM8Lfzby7Xb9bMv_H3Cp6A</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Dam-Larsen, S</creator><creator>Franzmann, M</creator><creator>Andersen, I B</creator><creator>Christoffersen, P</creator><creator>Jensen, L B</creator><creator>Sørensen, T I A</creator><creator>Becker, U</creator><creator>Bendtsen, F</creator><general>BMJ Publishing Group Ltd and British Society of Gastroenterology</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>Copyright 2004 by Gut</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20040501</creationdate><title>Long term prognosis of fatty liver: risk of chronic liver disease and death</title><author>Dam-Larsen, S ; Franzmann, M ; Andersen, I B ; Christoffersen, P ; Jensen, L B ; Sørensen, T I A ; Becker, U ; Bendtsen, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b586t-b44e54d14edf25d12cf35e957faa80c2691825cec12697e11f61f9bdc21752b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alcohol use</topic><topic>ASAT</topic><topic>aspartate aminotransferase</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>BMI</topic><topic>body mass index</topic><topic>Chronic Disease</topic><topic>cirrhosis</topic><topic>Data collection</topic><topic>Diabetes</topic><topic>epidemiology</topic><topic>fatty liver</topic><topic>Fatty Liver - complications</topic><topic>Fatty Liver, Alcoholic - complications</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis</topic><topic>Hospitals</topic><topic>Humans</topic><topic>ICD</topic><topic>Insulin resistance</topic><topic>International Classification of Diseases</topic><topic>Liver</topic><topic>liver biopsy</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver diseases</topic><topic>LPR</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>NAFLD</topic><topic>NASH</topic><topic>non-alcoholic fatty liver disease</topic><topic>non-alcoholic steatohepatitis</topic><topic>Obesity</topic><topic>Pathology</topic><topic>Patients</topic><topic>Personal identification numbers</topic><topic>Prognosis</topic><topic>Risk Assessment</topic><topic>Studies</topic><topic>Survival Analysis</topic><topic>the national registry of patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dam-Larsen, S</creatorcontrib><creatorcontrib>Franzmann, M</creatorcontrib><creatorcontrib>Andersen, I B</creatorcontrib><creatorcontrib>Christoffersen, P</creatorcontrib><creatorcontrib>Jensen, L B</creatorcontrib><creatorcontrib>Sørensen, T I A</creatorcontrib><creatorcontrib>Becker, U</creatorcontrib><creatorcontrib>Bendtsen, F</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dam-Larsen, S</au><au>Franzmann, M</au><au>Andersen, I B</au><au>Christoffersen, P</au><au>Jensen, L B</au><au>Sørensen, T I A</au><au>Becker, U</au><au>Bendtsen, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long term prognosis of fatty liver: risk of chronic liver disease and death</atitle><jtitle>Gut</jtitle><addtitle>Gut</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>53</volume><issue>5</issue><spage>750</spage><epage>755</epage><pages>750-755</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><eissn>1458-3288</eissn><coden>GUTTAK</coden><abstract>Background and aims: Fatty liver is a common histological finding in human liver biopsy specimens. It affects 10–24% of the general population and is believed to be a marker of risk of later chronic liver disease. The present study examined the risk of development of cirrhotic liver disease and the risk of death in a cohort diagnosed with pure fatty liver without inflammation. Methods: A total of 215 patients who had a liver biopsy performed during the period 1976–1987 were included in the study. The population consisted of 109 non-alcoholic and 106 alcoholic fatty liver patients. Median follow up time was 16.7 (0.2–21.9) years in the non-alcoholic and 9.2 (0.6–23.1) years in the alcoholic group. Systematic data collection was carried out by review of all medical records. All members of the study cohort were linked through their unique personal identification number to the National Registry of Patients and the nationwide Registry of Causes of Death, and all admissions, discharge diagnoses, and causes of death were obtained. Results: In the non-alcoholic fatty liver group, one patient developed cirrhosis during the follow up period compared with 22 patients in the alcoholic group. Survival estimates were significantly (p<0.01) different between the two groups, for men as well as for women, with a higher death rate in the alcoholic fatty liver group. Survival estimates in the non-alcoholic fatty liver group were not different from the Danish population. Conclusions: This study revealed that patients with type 1 non-alcoholic fatty liver disease have a benign clinical course without excess mortality.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Society of Gastroenterology</pub><pmid>15082596</pmid><doi>10.1136/gut.2003.019984</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0017-5749 |
| ispartof | Gut, 2004-05, Vol.53 (5), p.750-755 |
| issn | 0017-5749 1468-3288 1458-3288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1774026 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Alcohol use ASAT aspartate aminotransferase Biological and medical sciences Biomarkers - blood BMI body mass index Chronic Disease cirrhosis Data collection Diabetes epidemiology fatty liver Fatty Liver - complications Fatty Liver, Alcoholic - complications Female Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen Hepatitis Hospitals Humans ICD Insulin resistance International Classification of Diseases Liver liver biopsy Liver cirrhosis Liver Cirrhosis - etiology Liver Cirrhosis - pathology Liver diseases LPR Male Medical prognosis Medical records Medical sciences Middle Aged Mortality NAFLD NASH non-alcoholic fatty liver disease non-alcoholic steatohepatitis Obesity Pathology Patients Personal identification numbers Prognosis Risk Assessment Studies Survival Analysis the national registry of patients |
| title | Long term prognosis of fatty liver: risk of chronic liver disease and death |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T15%3A11%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20term%20prognosis%20of%20fatty%20liver:%20risk%20of%20chronic%20liver%20disease%20and%20death&rft.jtitle=Gut&rft.au=Dam-Larsen,%20S&rft.date=2004-05-01&rft.volume=53&rft.issue=5&rft.spage=750&rft.epage=755&rft.pages=750-755&rft.issn=0017-5749&rft.eissn=1468-3288&rft.coden=GUTTAK&rft_id=info:doi/10.1136/gut.2003.019984&rft_dat=%3Cproquest_pubme%3E4014108291%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1779324890&rft_id=info:pmid/15082596&rfr_iscdi=true |